Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949779 | 0.86 | KMT2A (0.67) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL20540167 | 0.84 | KMT2A (0.61) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL10340271 | 0.84 | KDM4E (0.77) | ALDH1A1KMT2ASMN1; SMN2HPGDGAA | |
| SCHEMBL1463287 | 0.82 | GRIK1 (0.72) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL27567020 | 0.80 | HCAR2 (0.53) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL27546664 | 0.79 | NPC1 (0.60) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL5594906 | 0.79 | CFD (0.74) | CFDALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL30222219 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL28642375 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KMT2ANPC1RAB9AHTT | |
| SCHEMBL2938380 | 0.77 | KMT2A (0.69) | ALDH1A1KMT2ANPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809492-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1185261-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-1185261-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-6180675-B1 | THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2001-01-30 | — | — | US | disclosed |
| WO-2000076495-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6005008-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5886044-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0809492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025157-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | CFD 1435/4885ALDH1A1 2239/4885KMT2A 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.